Saniona AB (SANION) Stock Analysis | Price, Returns, Financials & Key Metrics

Mojo Score Change: Saniona AB has changed its score on 27 Nov 2025. Click here to unlock latest mojo score!

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

OPERATING CASH FLOW(Y) Highest at SEK 236.92 MM
NET SALES(HY) Higher at SEK 323.18 MM
NET PROFIT(HY) Higher at SEK 266.08 MM

With ROE of 60.17%, it has a attractive valuation with a 5.53 Price to Book Value

Consistent Returns over the last 3 years

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

SEK 2,059 Million (Small Cap)

P/E

9.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.85

Return on Equity

60.17%

Price to Book

5.78

Revenue and Profits:

Net Sales:

9 Million

(Quarterly Results - Jun 2025)

Net Profit:

-22 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

56.26%

6 Months

109.34%

1 Year

167.21%

2 Years

262.46%

3 Years

546.49%

4 Years

126.27%

5 Years

7.9%

Saniona AB for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Strong Financial Performance Positions Saniona AB as a Promising Investment Opportunity

Saniona AB, a small-cap company, has demonstrated impressive financial results for the quarter ending March 2025, showcasing a robust operational performance that may attract investor interest.

The company reported an operating cash flow of SEK 236.92 MM, marking its highest level to date. This positive cash flow is indicative of the company's ability to generate liquidity from its operations, which is crucial for sustaining growth and funding future initiatives.

In terms of revenue, Saniona AB achieved net sales of SEK 323.18 MM for the half-year period, reflecting a significant increase compared to previous periods. This growth in sales is complemented by a net profit of SEK 266.08 MM, further solidifying the company's financial health.

Additionally, the return on capital employed (ROCE) reached an impressive 160.68%, highlighting the effectiven...

Saniona AB Reports Strong Financial Metrics and Significant Yearly Return Performance

Saniona AB, a small-cap pharmaceutical company, has recently revised its evaluation, reflecting significant changes in financial metrics. The company reported strong quarterly results, with impressive operating cash flow and net sales, alongside favorable valuation ratios and performance indicators, showcasing its robust market presence.

Saniona AB's Valuation Upgrade Highlights Strong Financial Performance and Growth Potential

Saniona AB, a small-cap pharmaceutical company, has recently seen a revision in its valuation grade, reflecting an attractive financial status. Key performance indicators include a high return on equity of 60.17% and a low PEG ratio of 0.02, indicating potential undervaluation relative to growth.

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

135.60%

EBIT Growth (5y)

32.76%

EBIT to Interest (avg)

-8.69

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.03

Sales to Capital Employed (avg)

0.61

Tax Ratio

7.99%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

17.87%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

5.53

EV to EBIT

7.30

EV to EBITDA

7.07

EV to Capital Employed

30.62

EV to Sales

4.91

PEG Ratio

0.03

Dividend Yield

ROCE (Latest)

419.47%

ROE (Latest)

60.17%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bearish

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Dow Theory

Mildly Bullish

OBV

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -5.10% vs -96.87% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -216.84% vs -92.31% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "9.30",
          "val2": "9.80",
          "chgp": "-5.10%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-22.90",
          "val2": "-13.80",
          "chgp": "-65.94%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.00",
          "val2": "0.80",
          "chgp": "25.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-22.20",
          "val2": "19.00",
          "chgp": "-216.84%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-2,635.00%",
          "val2": "-1,602.10%",
          "chgp": "-103.29%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 1,892.26% vs 9.80% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 296.97% vs 54.73% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "334.70",
          "val2": "16.80",
          "chgp": "1,892.26%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "246.80",
          "val2": "-69.70",
          "chgp": "454.09%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "38.90",
          "val2": "24.90",
          "chgp": "56.22%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "188.70",
          "val2": "-95.80",
          "chgp": "296.97%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "714.50%",
          "val2": "-4,711.80%",
          "chgp": "542.63%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

9.30

9.80

-5.10%

Operating Profit (PBDIT) excl Other Income

-22.90

-13.80

-65.94%

Interest

1.00

0.80

25.00%

Exceptional Items

0.00

Consolidate Net Profit

-22.20

19.00

-216.84%

Operating Profit Margin (Excl OI)

-2,635.00%

-1,602.10%

-103.29%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is -5.10% vs -96.87% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -216.84% vs -92.31% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

334.70

16.80

1,892.26%

Operating Profit (PBDIT) excl Other Income

246.80

-69.70

454.09%

Interest

38.90

24.90

56.22%

Exceptional Items

0.00

Consolidate Net Profit

188.70

-95.80

296.97%

Operating Profit Margin (Excl OI)

714.50%

-4,711.80%

542.63%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 1,892.26% vs 9.80% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 296.97% vs 54.73% in Dec 2023

All Annual Results

Company CV

About Saniona AB

Saniona AB

Pharmaceuticals & Biotechnology

Saniona AB is a Sweden-based company active in the field of biotechnology. It operates in the area of drugs targeting ion channels to develop therapeutics for pain, central nervous system, and inflammatory or autoimmune diseases. The Company develops a technology platform which enables investigation of all types of ion channel drug targets. Its research is focused on GABAA receptors, nicotinic acetylcholine receptors and potassium channels. The clinical pipeline includes: AN788, a clinical candidate for second line treatment of major depressive disorder (MDD); AN761, to be developed for cognition deficits in schizophrenia and Alzheimer's disease; AN363, a candidate for treatment of pain disorders; and AN346, an anti-inflammatory treatment in inflammatory bowel disease (IBD); as well as several other projects. The Company is engaged in partnerships with Janssen Pharmaceuticals Inc, Pfizer Inc and Atlas Venture Inc.

Company Coordinates

Company Details

Baltorpvej 154 , BALLERUP None : 2750

Tel:

https://saniona.com/

Registrar Details

Saniona AB

1Day

52 Week

CASH

FII

DII

Promoter

MarketsMojo — Loved in India, Now Global

Dashboard

With ROE of 60.17%, it has a attractive valuation with a 5.53 Price to Book Value

Consistent Returns over the last 3 years

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Strong Financial Performance Positions Saniona AB as a Promising Investment Opportunity

Saniona AB Reports Strong Financial Metrics and Significant Yearly Return Performance

Saniona AB's Valuation Upgrade Highlights Strong Financial Performance and Growth Potential

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Annual Results Snapshot (Consolidated) - Dec'24

About Saniona AB

Company Coordinates